Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease

Figure 3 Effects of vitamin E treatment on results of noninvasive scoring systems of hepatic fibrosis. ^aIndicate a difference compared with baseline values (P < 0.05). A: Evolution of FIB-4 index during the study period. FIB-4 index in all patients decreased from baseline to 6 and 12 mo (P = 0.015 and P = 0.035, respectively). The FIB-4 index in the CC/CG group also decreased from baseline to 6 and 12 mo (P = 0.014 and P = 0.017, respectively); B: Evolution of APRI during the study period. APRI in all patients decreased from baseline to 6 and 12 mo (P < 0.001 and P < 0.001, respectively). APRI in the CC/CG group decreased from baseline to 6 and 12 mo (P = 0.004 and P < 0.001, respectively). APRI in the GG group also decreased from baseline to 6 and 12 mo (P = 0.028 and P = 0.036, respectively). FIB-4: Fibrosis-4; APRI: Aminotransferase-to-platelet index.